Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 301

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 301
---
16,217,655
    )

    General and administrative

    4,314,176

    4,144,648

    169,528

    Total operating expenses

    17,649,492

    29,764,720

    (12,115,228
    )

    Loss from operations

    (17,649,492
    )

    (29,764,720
    )

    12,115,228

    Other income (expense)

    Employee retention tax credit

    -

    334,443

    (334,443
    )

    Grant income

    57,627

    42,466

    15,161

    Interest expense

    (4,138,301
    )

    (18,688
    )

    (4,119,613
    )

    Interest income

    361,632

    89,673

    271,959

    Change in fair value of derivative liability

    (313,772
    )

    -

    (313,772
    )

    Total other income (expense)

    (4,032,814
    )

    447,894

    (4,146,265
    )

    Net loss
     
    $
    (21,682,306
    )
     
    $
    (29,316,826
    )
     
    $
    7,968,963

    Series A Preferred cash dividend

    (2,089
    )

    -

    (2,089
    )

    Warrant modification

    (965,177
    )

    -

    (965,177
    )

    Net loss attributable to common shareholders
     
    $
    (22,649,572
    )
     
    $
    (29,316,826
    )
     
    $
    6,667,254

Research and Development Expenses. The following table summarizes our research and development expenses by program for the periods presented.

    Year ended

    December 31,

    Change

    2024

    2023

    (in thousands)

    Direct program costs:

    IFx-2.0
     
    $
    7,286,319

    $
    5,679,869

    $
    1,606,450

    Preclinical research costs

    702,628

    316,